Skip to main content
Clinical Trials/NCT02544594
NCT02544594
Completed
Phase 4

Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction

LMU Klinikum1 site in 1 country42 target enrollmentNovember 2015

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Cardiogenic Shock
Sponsor
LMU Klinikum
Enrollment
42
Locations
1
Primary Endpoint
Left ventricular ejection fraction (LVEF) on day 30
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This study compares standard treatment plus Extra-Corporal Life Support (ECLS) versus standard treatment alone in patients with cardiogenic shock due to myocardial infarction.

Detailed Description

Cardiogenic shock is a serious complication of a myocardial infarction. Despite optimal treatment the mortality in patients with cardiogenic shock still exceeds 50% and surviving patients mostly suffer from severe heart failure due to an impaired cardiac function. This study compares standard treatment plus Extra-Corporal Life Support (ECLS) versus standard treatment alone in patients with cardiogenic shock due to myocardial infarction. The main study hypothesis is to explore if additional treatment with ECLS preserves cardiac function (left ventricular ejection fraction) in patients with cardiogenic shock complicating acute myocardial infarction.

Registry
clinicaltrials.gov
Start Date
November 2015
End Date
March 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
LMU Klinikum
Responsible Party
Principal Investigator
Principal Investigator

PD Dr. Stefan Brunner

PD Dr. med.

LMU Klinikum

Eligibility Criteria

Inclusion Criteria

  • Cardiogenic shock complicating acute myocardial (STEMI or NSTEMI) with
  • intended revascularization (PCI or CABG)
  • Systolic blood pressure \< 90 mmHg \> 30 min or inotropes required to maintain pressure \> 90 mmHg during systole
  • Signs of left heart insufficiency and pulmonary congestion
  • Signs of impaired organ perfusion with at least one of the following:
  • Altered mental status
  • Cold, clammy skin
  • Urine output \<30 ml/h
  • Serum lactate \>2mmol/l
  • Informed consent

Exclusion Criteria

  • Resuscitation \> 60 minutes, ischemia \> 10 minutes
  • No intrinsic heart action
  • Cerebral deficit with fixed dilated pupils
  • Mechanical infarction complication
  • Onset of shock \> 12 h
  • Severe peripheral artery disease
  • Aortic regurgitation \> II.°
  • Age \> 80 years
  • shock of other cause
  • Other severe concomitant disease

Outcomes

Primary Outcomes

Left ventricular ejection fraction (LVEF) on day 30

Time Frame: 30 days

Secondary Outcomes

  • potentia hydrogenic levels(48 hours)
  • Length of ICU stay(30 days)
  • 30-day mortality(30 days)
  • Long-term mortality at 12 months(up to 12 months)
  • Neurological Outcome (modified Rankin Scale)(up to 12 months)
  • MACE (defined as cardiac death, non-fatal myocardial re-infarction, rehospitalisation for cardiac reasons and the need of CABG or PCI)(up to 12 months)
  • Lactate levels(up to 48 hours)
  • Length of mechanical ventilation(30 days)

Study Sites (1)

Loading locations...

Similar Trials